Taubman Institute Founder & Director to receive ALS award

The ALS Association Michigan Chapter has named Mr. A. Alfred Taubman, founder and chair of the A. Alfred Taubman Medical Research Institute, and Eva L. Feldman, M.D., Ph.D., the institute’s director, as the 2014 recipients of the association’s Legacy of Hope Award.

The award honors individuals who effect positive changes within the ALS community and demonstrate a remarkable commitment to the betterment of treatment for ALS patients, and the research necessary to find the cure for ALS.

Through his establishment of the Taubman Institute at the University of Michigan, as well as for his philanthropic support of Dr. Feldman’s laboratory, Mr. Taubman has created an environment where scientists are working on ALS-related research ranging from imaging techniques to provide early diagnosis, to Dr. Feldman’s landmark trial of a first-ever stem cell treatment for ALS. To date, 22 patients have received injections of specially engineered stem cells directly to their spinal cords in the FDA-approved trial, which is testing the ability of the stem cells to replace dying motor neurons.

“Mr. Taubman and I are deeply grateful to be selected as the inaugural recipients of this honor,” said Dr. Feldman. “We greatly appreciate the recognition of our work at the Taubman Institute to create hope for ALS patients and their families, and are proud to accept it as representatives of the many other researchers, philanthropists and caregivers striving every day in the quest for new cures and treatments.”

Dr. Feldman and Mr. Taubman will be honored at the Legacy of Hope evening sponsored by the ALS Association Michigan Chapter on April 3. The black-tie gala featuring a reception, dinner, auction and awards program will be held at the Townsend Hotel in Birmingham beginning at 6 p.m.  

For information about tickets and sponsorship opportunities, visit www.alsa-michigan.org or call (248) 680-6540.

 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

 

Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster

 

video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists